OBJECTIVE: This study was conducted to determine the expression pattern, regulation and function of CCL28 and CCR10 in rheumatoid arthritis (RA) pathogenesis. METHODS: Expression of CCL28 and CCR10 was assessed in RA compared with other arthritis synovial tissues (STs) or fluids (SFs) by histology or ELISA. The factors modulating CCL28 and CCR10 expression were identified in RA myeloid and endothelial cells by ELISA, FACS and Western blotting. The mechanism by which CCL28 ligation promotes RA angiogenesis was examined in control and CCR10-knockdown endothelial cell chemotaxis and capillary formation. RESULTS: CCL28 and/or CCR10 expression levels were accentuated in STs and SFs of patients with joint disease compared with normal controls and they were predominately coexpressed in RA myeloid and endothelial cells. We show that protein expression of CCL28 and CCR10 was modulated by tumour necrosis factor (TNF)-α and toll-like receptor 4 ligation in RA monocytes and endothelial cells and by interleukin (IL)-6 stimulation in RA macrophages. Neutralisation of CCL28 in RA SF or blockade of CCR10 on human endothelial progenitor cells (EPCs) significantly reduced SF-induced endothelial migration and capillary formation, demonstrating that ligation of joint CCL28 to endothelial CCR10+ cells is involved in RA angiogenesis. We discovered that angiogenesis driven by ligation of CCL28 to CCR10 is linked to the extracellular signal regulated kinase (ERK) cascade, as CCR10-knockdown cells exhibit dysfunctional CCL28-induced ERK signalling, chemotaxis and capillary formation. CONCLUSIONS: The overexpression of CCL28 and CCR10 in RA ST and their contribution to EPC migration into RA joints support the CCL28/CCR10 cascade as a potential therapeutic target for RA. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
OBJECTIVE: This study was conducted to determine the expression pattern, regulation and function of CCL28 and CCR10 in rheumatoid arthritis (RA) pathogenesis. METHODS: Expression of CCL28 and CCR10 was assessed in RA compared with other arthritis synovial tissues (STs) or fluids (SFs) by histology or ELISA. The factors modulating CCL28 and CCR10 expression were identified in RA myeloid and endothelial cells by ELISA, FACS and Western blotting. The mechanism by which CCL28 ligation promotes RA angiogenesis was examined in control and CCR10-knockdown endothelial cell chemotaxis and capillary formation. RESULTS:CCL28 and/or CCR10 expression levels were accentuated in STs and SFs of patients with joint disease compared with normal controls and they were predominately coexpressed in RA myeloid and endothelial cells. We show that protein expression of CCL28 and CCR10 was modulated by tumour necrosis factor (TNF)-α and toll-like receptor 4 ligation in RA monocytes and endothelial cells and by interleukin (IL)-6 stimulation in RA macrophages. Neutralisation of CCL28 in RA SF or blockade of CCR10 on human endothelial progenitor cells (EPCs) significantly reduced SF-induced endothelial migration and capillary formation, demonstrating that ligation of joint CCL28 to endothelial CCR10+ cells is involved in RA angiogenesis. We discovered that angiogenesis driven by ligation of CCL28 to CCR10 is linked to the extracellular signal regulated kinase (ERK) cascade, as CCR10-knockdown cells exhibit dysfunctional CCL28-induced ERK signalling, chemotaxis and capillary formation. CONCLUSIONS: The overexpression of CCL28 and CCR10 in RA ST and their contribution to EPC migration into RA joints support the CCL28/CCR10 cascade as a potential therapeutic target for RA. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Nathan D Chamberlain; Olga M Vila; Michael V Volin; Suncica Volkov; Richard M Pope; William Swedler; Arthur M Mandelin; Shiva Shahrara Journal: J Immunol Date: 2012-06-01 Impact factor: 5.422
Authors: Andrea Facciabene; Xiaohui Peng; Ian S Hagemann; Klara Balint; Andrea Barchetti; Li-Ping Wang; Phyllis A Gimotty; C Blake Gilks; Priti Lal; Lin Zhang; George Coukos Journal: Nature Date: 2011-07-13 Impact factor: 49.962
Authors: Karen M Scanlon; Richard J Hawksworth; Stephen J Lane; Bernard P Mahon Journal: Int Arch Allergy Immunol Date: 2011-03-29 Impact factor: 2.749
Authors: Sarah R Pickens; Nathan D Chamberlain; Michael V Volin; Richard M Pope; Nicholas E Talarico; Arthur M Mandelin; Shiva Shahrara Journal: Arthritis Rheum Date: 2012-08
Authors: J Pan; E J Kunkel; U Gosslar; N Lazarus; P Langdon; K Broadwell; M A Vierra; M C Genovese; E C Butcher; D Soler Journal: J Immunol Date: 2000-09-15 Impact factor: 5.422
Authors: B Homey; W Wang; H Soto; M E Buchanan; A Wiesenborn; D Catron; A Müller; T K McClanahan; M C Dieu-Nosjean; R Orozco; T Ruzicka; P Lehmann; E Oldham; A Zlotnik Journal: J Immunol Date: 2000-04-01 Impact factor: 5.422
Authors: Gabriela Hernandez-Molina; Amanda M Burkhardt; Guadalupe Lima; Albert Zlotnik; Jose L Betanzos; Susana Bahena; Luis Llorente Journal: Rheumatol Int Date: 2015-01-08 Impact factor: 2.631
Authors: Hatem A Elshabrawy; Michael V Volin; Abdul B Essani; Zhenlong Chen; Iain B McInnes; Katrien Van Raemdonck; Karol Palasiewicz; Shiva Arami; Mark Gonzalez; Hossam M Ashour; Seung-Jae Kim; Guofei Zhou; David A Fox; Shiva Shahrara Journal: Angiogenesis Date: 2018-01-11 Impact factor: 9.596
Authors: Zhenlong Chen; Jacob M Haus; Lin Chen; Stephanie C Wu; Norifumi Urao; Timothy J Koh; Richard D Minshall Journal: FASEB J Date: 2020-03-02 Impact factor: 5.191